Govt Moves New Proposal Before HC on Glivec Case (India)
This article was originally published in PharmAsia News
Responding to an appeal from Novartis, the Indian government has proposed allowing the chairman and vice-chairman of the Intellectual Property Appellate Board (IPAB) to hear the company's appeal regarding the cancer drug Glivec. In August, the pharmaceutical firm had filed a petition with the Madras High Court, requesting that Shri S. Chandrasekaran, the board's technical member, not hear the appeal, as he had previously refused a patent for the drug. A Novartis spokesperson reported the firm is considering the government's proposal. Legal analysts say it is unlikely that IPAB will reverse its decision. The Madras patent office rejected Novartis' patent application for Glivec in January 2006, arguing that Glivec's innovation did not meet the requirements of Section 3(d), which stipulates that modifications of known medicines cannot be patented unless they make the drug significantly more effective. (Click here for more
You may also be interested in...
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.